Methylhonokiol attenuates neuroinflammation: A role for cannabinoid receptors?

Journal of Neuroinflammation

Volumn 9, Issue , 2012, Pages

  Gertsch, Jürg ^a   Anavi Goffer, Sharon ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b ARIEL UNIVERSITY   (Israel)

Author keywords

Alzheimer's disease; Cannabinoids; Endocannabinoid system; Magnolia grandiflora; Medicinal plant; Methylhonokiol

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4' O METHYLHONOKIOL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ANTIINFLAMMATORY AGENT; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; FATTY ACID AMIDASE; UNCLASSIFIED DRUG; ANANDAMIDE; HONOKIOL; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METHYLHONOKIOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; VANILLOID RECEPTOR 1;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ASTROCYTE; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SAFETY; MICROGLIA; MOLECULAR DYNAMICS; MYELOID PROGENITOR CELL; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; NOTE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANTIOXIDANT ACTIVITY; CELL MIGRATION; ENZYME INHIBITION; HUMAN; IN VITRO STUDY; NEUROTOXICITY; PATHOPHYSIOLOGY; PROTEIN PROTEIN INTERACTION;

EID: 84862314657     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-9-135     Document Type: Note

References (45)

1. Lee YJ, Choi DY, Choi IS, Kim KH, Kim YH, Kim HM, Lee K, Cho WG, Jung JK, Han SB, Han JY, Nam SY, Yun YW, Jeong JH, Oh KW, Hong JT. Inhibitory effect of 4-O-methylhonokiol on lipopolysaccharide-induced neuroinflammation, amyloidogenesis and memory impairment via inhibition of nuclear factor-kappaB in vitro and in vivo models. J Neuroinflammation 2012, 9:35. 10.1186/1742-2094-9-35, 3323460, 22339795.
2. Lee YJ, Choi DY, Lee YK, Lee YM, Han SB, Kim YH, Kim KH, Nam SY, Lee BJ, Kang JK, Yun YW, Oh KW, Hong JT. 4-O-methylhonokiol prevents memory impairment in the Tg2576 Transgenic Mice Model of Alzheimer's disease via regulation of β-Secretase activity. J Alzheimers Dis 2012, 29:677-690.
3. Choi IS, Lee YJ, Choi DY, Lee YK, Lee YH, Kim KH, Kim YH, Jeon YH, Kim EH, Han SB, Jung JK, Yun YP, Oh KW, Hwang DY, Hong JT. 4-O-methylhonokiol attenuated memory impairment through modulation of oxidative damage of enzymes involving amyloid-β generation and accumulation in a mouse model of Alzheimer's disease. J Alzheimers Dis 2011, 27:127-141.
4. Lee YJ, Choi IS, Park MH, Lee YM, Song JK, Kim YH, Kim KH, Hwang DY, Jeong JH, Yun YP, Oh KW, Jung JK, Han SB, Hong JT. 4-O-Methylhonokiol attenuates memory impairment in presenilin 2 mutant mice through reduction of oxidative damage and inactivation of astrocytes and the ERK pathway. Free Radic Biol Med 2011, 50:66-77. 10.1016/j.freeradbiomed.2010.10.698, 20974250.
5. Lee YK, Choi IS, Ban JO, Lee HJ, Lee US, Han SB, Jung JK, Kim YH, Kim KH, Oh KW, Hong JT. 4-O-methylhonokiol attenuated β-amyloid-induced memory impairment through reduction of oxidative damages via inactivation of p38 MAP kinase. J Nutr Biochem 2011, 22:476-486. 10.1016/j.jnutbio.2010.04.002, 20688501.
6. http://worldwide.espacenet.com/publicationDetails/originalDocument?CC = EP&NR = 2327402&KC = &FT = E.
7. Lee YK, Yuk DY, Kim TI, Kim YH, Kim KT, Kim KH, Lee BJ, Nam SY, Hong JT. Protective effect of the ethanol extract of Magnolia officinalis and 4-O-methylhonokiol on scopolamine-induced memory impairment and the inhibition of acetylcholinesterase activity. J Nat Med 2009, 63:274-282. 10.1007/s11418-009-0330-z, 2690856, 19343477.
8. Lee JW, Lee YK, Lee BJ, Nam SY, Lee SI, Kim YH, Kim KH, Oh KW, Hong JT. Inhibitory effect of ethanol extract of Magnolia officinalis and 4-O-methylhonokiol on memory impairment and neuronal toxicity induced by beta-amyloid. Pharmacol Biochem Behav 2010, 95:31-40. 10.1016/j.pbb.2009.12.003, 20004682.
9. Schuehly W, Paredes JM, Kleyer J, Huefner A, Anavi-Goffer S, Raduner S, Altmann KH, Gertsch J. Mechanisms of osteoclastogenesis inhibition by a novel class of biphenyl-type cannabinoid CB(2) receptor inverse agonists. Chem Biol 2011, 18:1053-1064. 10.1016/j.chembiol.2011.05.012, 21867920.
10. Freund TF, Katona I, Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 2003, 83:1017-1066.
11. Alger BE. Endocannabinoids at the synapse a decade after the Dies Mirabilis (29 March 2001): what we still do not know. J Physiol 2012, 590:2203-2212.
12. Ohno-Shosaku T, Tanimura A, Hashimotodani Y, Kano M. Endocannabinoids and retrograde modulation of synaptic transmission. Neuroscientist 2012, 18:119-132. 10.1177/1073858410397377, 21531987.
13. Basu S, Dittel BN. Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease. Immunol Res 2011, 51:26-38. 10.1007/s12026-011-8210-5, 21626285.
14. Pacher P, Mechoulam R. Is lipid signaling through cannabinoid 2 receptors part of a protective system?. Prog Lipid Res 2011, 50:193-211. 10.1016/j.plipres.2011.01.001, 3062638, 21295074.
15. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, Greasley PJ, Hansen HS, Kunos G, Mackie K, Mechoulam R, Ross RA. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev 2010, 62:588-631. 10.1124/pr.110.003004, 2993256, 21079038.
16. Lunn CA. Updating the chemistry and biology of cannabinoid CB2 receptor-specific inverse agonists. Curr Top Med Chem 2010, 10:768-778. 10.2174/156802610791164193, 20370714.
17. Ashton JC, Glass M. The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Curr Neuropharmacol 2007, 5:73-80. 10.2174/157015907780866884, 2435344, 18615177.
18. Rivers JR, Ashton JC. The development of cannabinoid CBII receptor agonists for the treatment of central neuropathies. Cent Nerv Syst Agents Med Chem 2010, 10:47-64.
19. Stella N. Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 2010, 58(9):1017-30. 10.1002/glia.20983, 2919281, 20468046.
20. Bisogno T, Di Marzo V. Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders. CNS Neurol Disord Drug Targets 2010, 9:564-73.
21. Klein TW, Newton C, Larsen K, Lu L, Perkins I, Nong L, Friedman H. The cannabinoid system and immune modulation. J Leukoc Biol 2003, 74:486-96. 10.1189/jlb.0303101, 12960289.
22. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce?. Nat Rev Drug Discov 2008, 7:438-55. 10.1038/nrd2553, 18446159.
23. Palazuelos J, Davoust N, Julien B, Hatterer E, Aguado T, Mechoulam R, Benito C, Romero J, Silva A, Guzmán M, Nataf S, Galve-Roperh I. The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis. J Biol Chem 2008, 283:13320-13329. 10.1074/jbc.M707960200, 18334483.
24. Nomura DK, Morrison BE, Blankman JL, Long JZ, Kinsey SG, Marcondes MC, Ward AM, Hahn YK, Lichtman AH, Conti B, Cravatt BF. Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 2011, 334:809-813. 10.1126/science.1209200, 22021672.
25. Shohami E, Cohen-Yeshurun A, Magid L, Algali M, Mechoulam R. Endocannabinoids and traumatic brain injury. Br J Pharmacol 2011, 163:1402-1410. 10.1111/j.1476-5381.2011.01343.x, 3165950, 21418185.
26. Mechoulam R, Shohami E. Endocannabinoids and traumatic brain injury. Mol Neurobiol 2007, 36:68-74. 10.1007/s12035-007-8008-6, 17952651.
27. Tolón RM, Núñez E, Pazos MR, Benito C, Castillo AI, Martínez-Orgado JA, Romero J. The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages. Brain Res 2009, 1283:148-54.
28. Ramírez BG, Blázquez C, Gómez del Pulgar T, Guzmán M, de Ceballos ML. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 2005, 25:1904-1913. 10.1523/JNEUROSCI.4540-04.2005, 15728830.
29. Benito C, Núñez E, Tolón RM, Carrier EJ, Rábano A, Hillard CJ, Romero J. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J Neurosci 2003, 23:11136-11141.
30. Pacher P, Mackie K. Interplay of cannabinoid 2 (CB2) receptors with nitric oxide synthases, oxidative and nitrative stress, and cell death during remote neurodegeneration. J Mol Med (Berl) 2012, 90:347-351.
31. Gowran A, Noonan J, Campbell VA. The multiplicity of action of cannabinoids: implications for treating neurodegeneration. CNS Neurosci Ther 2011, 17:637-644. 10.1111/j.1755-5949.2010.00195.x, 20875047.
32. Benito C, Tolón RM, Castillo AI, Ruiz-Valdepeñas L, Martínez-Orgado JA, Fernández-Sánchez FJ, Vázquez C, Cravatt BF, Romero J. Beta amyloid exacerbates inflammation in astrocytes lacking fatty acid amide hydrolase through a mechanism involving Ppar-α, Ppar-γ and Trpv1, but not Cb(1) or Cb(2) Receptors. Br J Pharmacol 2012, 166:1474-1489. 10.1111/j.1476-5381.2012.01889.x, 22321194.
33. Correa F, Hernangómez M, Mestre L, Loría F, Spagnolo A, Docagne F, Di Marzo V, Guaza C. Anandamide enhances IL-10 production in activated microglia by targeting CB(2) receptors: roles of ERK1/2, JNK, and NF-kappaB. Glia 2010, 58:135-147. 10.1002/glia.20907, 19565660.
34. Jüttler E, Potrovita I, Tarabin V, Prinz S, Dong-Si T, Fink G, Schwaninger M. The cannabinoid dexanabinol is an inhibitor of the nuclear factor-kappa B (NF-kappa B). Neuropharmacology 2004, 47:580-592. 10.1016/j.neuropharm.2004.05.009, 15380375.
35. Chao LK, Liao PC, Ho CL, Wang EI, Chuang CC, Chiu HW, Hung LB, Hua KF. Anti-inflammatory bioactivities of honokiol through inhibition of protein kinase C, mitogen- activated protein kinase, and the NF-kappaB pathway to reduce LPS-induced TNFalpha and NO expression. J Agric Food Chem 2010, 58:3472-3478. 10.1021/jf904207m, 20192217.
36. Munroe ME, Arbiser JL, Bishop GA. Honokiol, a natural plant product, inhibits inflammatory signals and alleviates inflammatory arthritis. J Immunol 2007, 179:753-763.
37. Eikelenboom P, Veerhuis R, van Exel E, Hoozemans JJ, Rozemuller AJ, van Gool WA. The early involvement of the innate immunity in the pathogenesis of late-onset Alzheimer's disease: neuropathological, epidemiological and genetic evidence. Curr Alzheimer Res 2011, 8:142-50.
38. Zotova E, Nicoll JA, Kalaria R, Holmes C, Boche D. Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy. Alzheimers Res Ther 2010, 2:1. 10.1186/alzrt24, 2874260, 20122289.
39. Trepanier CH, Milgram NW. Neuroinflammation in Alzheimer's disease: are NSAIDs and selective COX-2 inhibitors the next line of therapy?. J Alzheimers Dis 2010, 21:1089-99.
40. Nimmo AJ, Vink R. Recent patents in CNS drug discovery: the management of inflammation in the central nervous system. Recent Pat CNS Drug Discov 2009, 4:86-95. 10.2174/157488909788452997, 19519558.
41. Böhmdorfer M, Maier-Salamon A, Taferner B, Reznicek G, Thalhammer T, Hering S, Hüfner A, Schühly W, Jäger W. In vitro metabolism and disposition of honokiol in rat and human livers. J Pharm Sci 2011, 100:3506-3516. 10.1002/jps.22536, 21404278.
42. Schühly W, Hüfner A, Pferschy-Wenzig EM, Prettner E, Adams M, Bodensieck A, Kunert O, Oluwemimo A, Haslinger E, Bauer R. Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxygenase-mediated LTB4-formation. Bioorg Med Chem 2009, 17:4459-4465. 10.1016/j.bmc.2009.05.018, 19481465.
43. Martinez M. Las plantas medicinales de Mexico 1959, 343-347. Editorial Botas, Mexico City, 4.
44. Ahmed SM, Abdelaleil AM. Antifungal activity of extracts and sesquiterpene lactones from Magnolia grandiflora L, (Magnoliaceae). Int J Agric Biol 2005, 7:638-642.
45. Schühly W, Khan I, Fischer NH. The ethnomedicinal uses of magnoliaceae from the southeastern United States as leads in drug discovery. Pharm Biol 2001, 39(Suppl 1):63-69.